Slc25A4 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein}}
SLC25A4 (Solute Carrier Family 25 Member 4), also known as ANT1 (Adenine Nucleotide Translocator 1), is a mitochondrial carrier protein that facilitates the exchange of ADP and ATP across the inner mitochondrial membrane.
SLC25A4 is a critical component of the mitochondrial oxidative phosphorylation system, responsible for transporting ATP generated in the mitochondria to the cytosol while importing ADP for phosphorylation. This translocase is essential for cellular energy production and has been implicated in various neurodegenerative diseases.
| Attribute |
Value |
| Protein Name |
Adenine Nucleotide Translocator 1 |
| UniProt ID |
P12235 |
| Gene Symbol |
SLC25A4 |
| Aliases |
ANT1, AAC1, SLC25A4 |
| Protein Length |
298 amino acids |
| Molecular Weight |
~33 kDa |
| Subcellular Location |
Mitochondria (inner membrane) |
| Topology |
6 transmembrane helices |
¶ Domain Structure
- N-terminal matrix loop: Contains regulatory sequences
- Transmembrane helices: 6 helices forming the pore
- Matrix loop: Substrate binding and transport cycle
- Cytosolic loop: Regulatory interactions
The primary reaction catalyzed by SLC25A4:
ATP(out) + ADP(in) → ATP(in) + ADP(out)
This exchange is:
- Electrogenic: 1:1 exchange of ATP⁴⁻ for ADP³⁻
- Bidirectional: Direction depends on cellular energy status
- Rate-limiting: Controls oxidative phosphorylation flux
| Property |
Value |
| Turnover rate |
~50-100 per second |
| Substrate affinity |
Low micromolar range |
| Inhibitors |
Atractyloside, bongkrekic acid |
| pH optimum |
7.0-7.5 |
- Dopaminergic neuron vulnerability: ANT1 dysfunction compromises ATP supply
- Mitochondrial complex I deficiency: Often coexists with ANT1 alterations
- PINK1/PARKIN pathway: May regulate ANT1 expression
- Therapeutic implications: Targeting ANT1 for neuroprotection
- Energy metabolism decline: Reduced ATP export capacity
- Amyloid-beta interaction: Aβ may inhibit ANT1 function
- Calcium dysregulation: Alters mitochondrial calcium handling with ANT1
- Motor neuron energy demands: High ATP requirements make neurons vulnerable
- Mitochondrial dysfunction: ANT1 contributes to mitochondrial failure
- Oxidative stress: ROS affects ANT1 function and expression
- Energy deficit: Mutant huntingtin impairs mitochondrial function
- ANT1 dysregulation: Altered expression and function in HD
- Transcriptional disruption: HTT affects ANT1 gene regulation
- Binding: ADP/ATP binds to cytosolic side
- Conformational change: C-to-M or M-to-C transition
- Release: Substrate released to opposite side
- Reset: Carrier returns to initial conformation
- Calcium: Matrix calcium modulates activity
- Nucleotides: ATP and ADP provide feedback
- Reactive oxygen species: Oxidative modification affects function
- Phosphorylation: Post-translational regulation
| Approach |
Target |
Status |
| Coenzyme Q10 |
Electron transport |
Clinical trials |
| ANT1 activators |
Direct activation |
Preclinical |
| Metabolic modulators |
Cellular energetics |
Research |
| Gene therapy |
SLC25A4 expression |
Experimental |
- Complex I (ND subunits): Functional coupling
- Complex V (ATP synthase): Direct substrate channeling
- Creatine kinase: Energy buffering system
- Hexokinase: Cytosolic ATP utilization
- VDAC: Outer membrane channel
- Cyclophilin D: Mitochondrial permeability transition
| Tissue |
Expression Level |
| Heart |
Highest |
| Skeletal muscle |
High |
| Brain |
Moderate |
| Kidney |
Moderate |
| Liver |
Low |
- Widely expressed in neurons
- High in Purkinje cells
- Detectable in glial cells
- Region-specific variations
- Serum ANT1: Possible biomarker for mitochondrial disease
- Mutation detection: Genetic testing for SLC25A4 variants
- Functional assays: Lymphoblastoid cell studies
- ANT1 knockout mice: Show mitochondrial myopathy
- Transgenic models: Overexpression studies
- Conditional knockouts: Tissue-specific deletion
The study of Slc25A4 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Klingenberg M. (2008). The ADP/ATP carrier in mitochondrial diseases. Journal of Inherited Metabolic Disease, 31(2): 237-246.
- Fiore C, et al. (1998). The mitochondrial ADP/ATP carrier: Evolutionary, functional, and structural aspects. Journal of Bioenergetics and Biomembranes, 30(1): 87-99.
- Brand MD, et al. (2005). The role of mitochondrial calcium in the regulation of oxidative phosphorylation. Cell Calcium, 38(3-4): 311-317.
- Wallace DC. (2005). Mitochondria and disease. Annual Review of Genomics and Human Genetics, 6: 275-301.
- Brower JV, et al. (2019). Mitochondrial carriers in neuronal function. Neurochemical Research, 44(1): 50-64.
- Milenkovic D, et al. (2013). SLC25A27 (UCP4) and mitochondrial function. Neurochemistry International, 62(6): 799-806.
- Azzu V, et al. (2010). The regulated expression of mitochondrial carriers. Biochimica et Biophysica Acta, 1797(6-7): 1041-1052.
- Palmieri L, et al. (2008). Mitochondrial carrier proteins. Cellular and Molecular Life Sciences, 65(5): 749-783.